Susceptibility rates in Latin American nations: Report from a regional resistance surveillance program (2011)

Brazilian Journal of Infectious Diseases

Volumn 17, Issue 6, 2013, Pages 672-681

  Jones, Ronald N ^a   Guzman Blanco, Manuel ^b   Gales, Ana C ^c   Gallegos, Belisario ^b   Castro, Aura Lucia Leal ^d   Martino, Marines Dalla Valle ^e   Vega, Silvio ^f   Zurita, Jeannete ^g   Cepparulo, Mario ^h   Castanheira, Mariana ^a  

^a JMI LABORATORIES   (United States)

^b Centro Medico Docente La Trinidad   (Venezuela)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^d GREBO Hops el Tunal   (Colombia)

^e HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^f Caja de Seguro Social   (Panama)

^g HOSPITAL VOZANDES   (Ecuador)

^h PFIZER INC   (United States)

Author keywords

Lactamases; ESBL; Latin America; Resistance; Surveillance

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; CARBAPENEM; CEFEPIME; CEFOPERAZONE; CEFOPERAZONE PLUS SULBACTAM; CEFTAZIDIME; CEFTRIAXONE; CLINDAMYCIN; COLISTIN; COTRIMOXAZOLE; DAPTOMYCIN; DOXYCYCLINE; ERYTHROMYCIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; MEROPENEM; OXACILLIN; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TIGECYCLINE; TOBRAMYCIN; VANCOMYCIN;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARGENTINA; ARTICLE; BETA HEMOLYTIC STREPTOCOCCUS; BRAZIL; CHILE; CITROBACTER; COAGULASE NEGATIVE STAPHYLOCOCCUS; COLOMBIA; CONTROLLED STUDY; COSTA RICA; DRUG MONITORING; ECUADOR; ENTEROBACTER; ENTEROCOCCUS; ESCHERICHIA COLI; GUATEMALA; HAEMOPHILUS INFLUENZAE; KLEBSIELLA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MEXICO; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; PANAMA; PERU; PROTEUS; PSEUDOMONAS AERUGINOSA; SERRATIA; STREPTOCOCCUS PNEUMONIAE; VENEZUELA;

ESBL; LATIN AMERICA; RESISTANCE; SURVEILLANCE; Β-LACTAMASES;

ANTI-BACTERIAL AGENTS; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; LATIN AMERICA; MICROBIAL SENSITIVITY TESTS; POPULATION SURVEILLANCE;

EID: 84888063977     PISSN: 14138670     EISSN: 16784391     Source Type: Journal    
DOI: 10.1016/j.bjid.2013.07.002     Document Type: Article

References (14)

1. Castanheira M., Costello A.J., Deshpande L.M., Jones R.N. Expansion of clonal complex 258 KPC-2-producing Klebsiella pneumoniae in Latin American hospitals: report of the SENTRY antimicrobial surveillance program. Antimicrob Agents Chemother 2012, 56:1668-1669.
2. Castanheira M., Sader H.S., Deshpande L.M., Fritsche T.R., Jones R.N. Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother 2008, 52:570-573.
3. Gales A.C., Castanheira M., Jones R.N., Sader H.S. Antimicrobial resistance among Gram-negative bacilli isolated from Latin America: results from SENTRY Antimicrobial Surveillance Program (Latin America, 2008-2010). Diagn Microbiol Infect Dis 2012, 73:354-360.
4. Rice L.B. Mechanisms of resistance and clinical relevance of resistance to beta-lactams, glycopeptides, and fluoroquinolones. Mayo Clin Proc 2012, 87:198-208.
5. Gould I.M. Clinical activity of anti-Gram-positive agents against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2011, 66:iv17-iv21.
6. Mendes R.E., Deshpande L., Rodriguez-Noriega E., Ross J.E., Jones R.N., Morfin-Otero R. First report of staphylococcal clinical isolates in Mexico with linezolid resistance caused by cfr: evidence of in vivo cfr mobilization. J Clin Microbiol 2010, 48:3041-3043.
7. Woodford N., Livermore D.M. Infections caused by Gram-positive bacteria: a review of the global challenge. J Infect 2009, 59:S4-S16.
8. Clinical and Laboratory Standards Institute M07-A9. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard 2012, CLSI, Wayne, PA, USA. ninth edition.
9. Clinical and Laboratory Standards Institute M100-S23. Performance standards for antimicrobial susceptibility testing: 23rd informational supplement 2013, CLSI, Wayne, PA, USA.
10. EUCAST Breakpoint tables for interpretation of MICs and zone diameters. Version 3.0 2013, Available at http://www.eucast.org/clinical_breakpoints/ [accessed 02.01.13].
11. Tygacil® Package Insert Wyeth Pharmaceuticals 2012, Available at www.tygacil.com [accessed January 2013].
12. Arias C.A., Mendes R.E., Stilwell M.G., Jones R.N., Murray B.E. Unmet needs and prospects for oritavancin in the management of vancomycin-resistant enterococcal infections. Clin Infect Dis 2012, 54:S8-S233.
13. Jones R.N., Sader H.S., Moet G.J., Farrell D.J. Declining antimicrobial susceptibility of Streptococcus pneumoniae in the United States: report from the SENTRY Antimicrobial Surveillance Program (1998-2009). Diagn Microbiol Infect Dis 2010, 68:334-336.
14. Papp-Wallace K.M., Endimiani A., Taracila M.A., Bonomo R.A. Carbapenems: past, present, and future. Antimicrob Agents Chemother 2011, 55:4943-4960.